Preventive Effects of Aspirin on Cardiovascular Complications in Prostate Cancer Cases after Endocrinotherapy

• DOI: 10.7314/apjcp.2015.16.12.4909
• Publication Date: 2015-09-10T14:37:29Z
• Authors: Xiao-Xia Li; Yong-Gang Zhang; Dong Wang; Yun-Fang Chen; Yan-Hua Shan
• Keywords: Aged, 80 and over; Male; Aspirin; Anti-Inflammatory Agents, Non-Steroidal; Prostatic Neoplasms; Androgen Antagonists; Middle Aged; Prognosis; 3. Good health; Survival Rate; 03 medical and health sciences; 0302 clinical medicine; Cardiovascular Diseases; Case-Control Studies; Humans; Aged; Follow-Up Studies; Neoplasm Staging

Objective: To explore the preventive effect of aspirin on cardiovascular complications in prostate cancer after endocrinotherapy. Materials and Methods: A total 92 patients with were divided into observation group (n=44) control (n=48). The was treated medical castration plus anti-androgenic drugs. Based above treatment, added aspirin. follow-up duration 2 years. changes partial prothrombin time (PT), activated thromboplastin (APTT), platelet aggregation rate (PAG), prostate-specific antigen (PSA) serum testosterone (T) before treatment as well incidence disease observed. Results: 2-year survival rates without 95.45% (42/44) 72.92% (35/48), respectively, significant difference presented between two groups by comparison to (<TEX>$x^2=8.5453$</TEX>, p=0.0035). There no statistical significance regarding PT (p>0.05). After APTT went down PAG gradually rise group, while increasingly group. Significant differences (p<0.01). Both PSA T levels decreased significantly (p<0.01), but there Conclusions: Application endocrinotherapy can easily lead occurrence disease, be prevented aspirin, affecting